Conduit Pharma Partners with Sarborg to Drive AI Innovation in Pharma

Conduit Pharmaceutical's collaboration with Sarborg strengthens their dedication to using AI-based solutions to promote growth, provide value to shareholders, and sustain a competitive advantage in the pharmaceutical industry. Conduit is dedicated to embracing innovative solutions to maintain a leading position in the pharmaceutical sector, minimizing dependence on conventional, labor-intensive approaches and leveraging the capabilities of AI-driven technology.

By engaging in this agreement with Sarborg, Conduit aims to tackle persistent issues in the pharmaceutical industry by striving to minimize human error in essential decision-making activities such as clinical development and asset identification. Conduit seeks to boost efficiency, reduce costs, and speed up timelines by minimizing human involvement through the integration of Sarborg's AI algorithm and cybernetics technology, ultimately optimizing the drug development process and providing Conduit with a major competitive edge.

Through this partnership, Conduit will acquire access to advanced predictive models and dashboards, allowing the Company to assess drug candidates, enhance clinical trials, and improve asset management using real-time data. When paired with learning algorithms, these tools will enable quicker, more precise decisions, enhancing efficiency and lowering expenses. By utilizing these insights, Conduit will stand out in a competitive market and obtain distinct data-driven knowledge that prepares the Company for success in both its existing and upcoming asset portfolio.